Mark R. Morris

4.0k citations

57 papers · 2.6k indexed · h-index 31

Impact in

Cancer Research top 2%
- Cancer, Hypoxia, and Metabolism
Pulmonary and Respiratory Medicine top 2%
- Renal cell carcinoma treatment
- Ferroptosis and cancer prognosis

Papers in

Cancer Research 17
- Cancer, Hypoxia, and Metabolism 11
Pulmonary and Respiratory Medicine 20
- Renal cell carcinoma treatment 11
- Cystic Fibrosis Research Advances 6

Co-authors: Farida Latif Eamonn R. Maher Dean Gentle Christopher J. Ricketts Dewi Astuti Masahiro Yao Takeshi Kishida Emma R. Woodward
Journals: Oncogene (7 papers)Neuro-Oncology (3 papers)The Journal of Pathology (2 papers)American Journal of Medical Genetics Part C Seminars in Medical Genetics (2 papers)Genes Chromosomes and Cancer (2 papers)
Partner nations: United Kingdom Japan France

In The Last Decade

Mark R. Morris

55 papers receiving 2.6k citations

Peers

Countries citing papers authored by Mark R. Morris

Since Specialization

Citations

This map shows the geographic impact of Mark R. Morris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark R. Morris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark R. Morris more than expected).

Fields of papers citing papers by Mark R. Morris

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark R. Morris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark R. Morris. The network helps show where Mark R. Morris may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mark R. Morris, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark R. Morris Line = papers co-authored together Mark R. Morris links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	FGF23 Expression Is a Promising Immunohistochemical Diagnostic Marker for Undifferentiated Pleomorphic Sarcoma of Bone (UPSb) Genes ·Hafid O. Al‐Hassi, Pedro Canelhas, Hannah Cooke, D. Batzler, A.T. Brini, Anders Zorn, Vaiyapuri P. Sumathi, Mark R. Morris, Stefania Niada	2024	0
2	PLGA–Nano-Encapsulated Disulfiram Inhibits Hypoxia-Induced NF-κB, Cancer Stem Cells, and Targets Glioblastoma In Vitro and In Vivo Molecular Cancer Therapeutics ·Vinodh Kannappan, 张国凯, ADA CASTILLO, Misty Sawatzky, Vincenzo d'Agostino, Holly A. Orndorff, Angel L. Armesilla, Mark R. Morris, Mohammad Najlah, Yoshihiro Miyake, Xiu‐Wu Bian, Weiguang Wang	2022	22
3	Genome-wide methylation analyses identifies Non-coding RNA genes dysregulated in breast tumours that metastasise to the brain Scientific Reports ·Rajendra P. Pangeni, N. I. Latyschew, David Huen, Åshild Skorpen, Timothy Dawson, Katherine M. Ashton, Charles H. Davis, Andrew Brodbelt, Michael D. Jenkinson, Ivan Bièche, Lu Yang, Farida Latif, John L. Darling, Tracy Warr, Mark R. Morris	2022	9
4	Cabozantinib as the causative agent of high-grade fever in a patient with a background of metastatic clear cell renal cell carcinoma: a case report Journal of Medical Case Reports ·I. Bellafiore, Mark R. Morris, Peggy Manders	2020	0
5	The epigenetic landscape of renal cancer Nature Reviews Nephrology ·Mark R. Morris, Farida Latif	2016	93
6	The relative DNA-shedding propensity of the palm and finger surfaces Science & Justice ·武宏斌, Mark R. Morris, Takara Tomy, Raul Sutton	2015	47
7	Perlman Syndrome: Overgrowth, Wilms Tumor Predisposition and DIS3L2 American Journal of Medical Genetics Part C Seminars in Medical Genetics ·Mark R. Morris, Dewi Astuti, Eamonn R. Maher	2013	34
8	Methylation profiling and evaluation of demethylating therapy in renal cell carcinoma Clinical Epigenetics ·Christopher J. Ricketts, Mark R. Morris, Dean Gentle, Salwati Shuib, Michael D. Brown, Noel W. Clarke, Wenbin Wei, Paul Nathan, Farida Latif, Eamonn R. Maher	2013	35
9	DNA methylation profiles of long- and short-term glioblastoma survivors Epigenetics ·Thoraia Shinawi, Victoria Hill, Dietmar Krex, Gabriele Schackert, Dean Gentle, Mark R. Morris, Wenbin Wei, Garth Cruickshank, Eamonn R. Maher, Farida Latif	2013	93
10	Bacillus subtilis natto: a non-toxic source of poly-γ-glutamic acid that could be used as a cryoprotectant for probiotic bacteria AMB Express ·Aditya Bhat, Victor U. Irorere, Marlian Hasrantih, David Hill, Gopal Kedia, Mark R. Morris, Dimitris Charalampopoulos, Iza Radecka	2013	72
11	Mutations in FLVCR2 Are Associated with Proliferative Vasculopathy and Hydranencephaly-Hydrocephaly Syndrome (Fowler Syndrome) The American Journal of Human Genetics ·Esther Meyer, Christopher J. Ricketts, Neil V. Morgan, Mark R. Morris, Shanaz Pasha, Louise Tee, Fatimah Rahman, Anne Bazin, Bettina Bessières, Pierre Déchelotte, VUILLE, Mudher Al‐Adnani, Tamás Marton, David Tannahill, Richard C. Trembath, Catherine Fallet‐Bianco, P. Cox, Denise Williams, Eamonn R. Maher	2010	46
12	Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics Genome Medicine ·Mark R. Morris, Eamonn R. Maher	2010	57
13	Epigenetic inactivation of the RASSF10 candidate tumor suppressor gene is a frequent and an early event in gliomagenesis Oncogene ·Victoria Hill, 弘若林, Dietmar Krex, Katja Robel, Calister U. Ezeh, A. Childs, Mark R. Morris, Dean Gentle, Andrew D. Chalmers, Eamonn R. Maher, Farida Latif	2010	47
14	Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma Oncogene ·Mark R. Morris, Christopher J. Ricketts, Dean Gentle, Fiona E. McRonald, Marco Trombetti, 云燕, M.D. Brown, Takeshi Kishida, Masahiro Yao, Rosamonde E. Banks, Noel W. Clarke, Farida Latif, Eamonn R. Maher	2010	166
15	CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma Molecular Cancer ·Fiona E. McRonald, Mark R. Morris, Dean Gentle, Laura Winchester, Dilair Baban, Jiannis Ragoussis, Noel W. Clarke, Michael D. Brown, Takeshi Kishida, Masahiro Yao, Farida Latif, Eamonn R. Maher	2009	65
16	Evaluation of a functional epigenetic approach to identify promoter region methylation in phaeochromocytoma and neuroblastoma Endocrine Related Cancer ·S. Sumanth Kori, Mark R. Morris, Dewi Astuti, Dean Gentle, Alberto Cascón, Fiona E. McRonald, Daniel Catchpoole, Mercedes Robledo, Hartmut P.H. Neumann, Farida Latif, Eamonn R. Maher	2008	22
17	Characterization of a 3;6 translocation associated with renal cell carcinoma Genes Chromosomes and Cancer ·Choi Chun Ho, Mahera Abdulrahman, Mark R. Morris, Elena Prigmore, Susan Gribble, Sukriadi, Dean Gentle, Steven Ready, Kanayo Umeh, Michael S. Wiesener, Takeshi Kishida, Masahiro Yao, Val Davison, José Luís Barbero, Carol Chu, Nigel P. Carter, Farida Latif, Eamonn R. Maher	2007	26
18	Identification of novel VHL targets that are associated with the development of renal cell carcinoma Oncogene ·Mahera Abdulrahman, Esther N. Maina, Mark R. Morris, Malgorzata Zatyka, Raju R. Raval, Rosamonde E. Banks, Michael S. Wiesener, Frances M. Richards, Claire M. Johnson, Farida Latif, Eamonn R. Maher	2006	17
19	Tumor Suppressor Activity and Epigenetic Inactivation of Hepatocyte Growth Factor Activator Inhibitor Type 2/SPINT2 in Papillary and Clear Cell Renal Cell Carcinoma Cancer Research ·Mark R. Morris, Dean Gentle, Mahera Abdulrahman, Esther N. Maina, Kunal Gupta, Rosamonde E. Banks, Michael S. Wiesener, Takeshi Kishida, Masahiro Yao, Bin Tean Teh, Farida Latif, Eamonn R. Maher	2005	95
20	Molecular genetic analysis of FIH-1, FH, and SDHB candidate tumour suppressor genes in renal cell carcinoma Journal of Clinical Pathology ·Mark R. Morris, Esther N. Maina, Neil V. Morgan, Dean Gentle, Dewi Astuti, Holger Moch, Takeshi Kishida, Masahiro Yao, Peter Schraml, Frances M. Richards, Farida Latif, Eamonn R. Maher	2004	56

About Mark R. Morris

Mark R. Morris is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine, Molecular Biology, Genetics and Process Chemistry and Technology, having authored 57 papers that have together received 2.6k indexed citations. Recurring topics across this work include Epigenetics and DNA Methylation (21 papers), Renal cell carcinoma treatment (11 papers), Cancer, Hypoxia, and Metabolism (11 papers), Renal and related cancers (10 papers), RNA modifications and cancer (8 papers), Cystic Fibrosis Research Advances (6 papers), Cancer-related gene regulation (5 papers) and Neutrophil, Myeloperoxidase and Oxidative Mechanisms (4 papers). The work is most often cited by research in Cancer Research (697 citations), Pulmonary and Respiratory Medicine (895 citations), Molecular Biology (1.7k citations), Oncology (276 citations) and Genetics (80 citations). Mark R. Morris has collaborated with scholars based in United Kingdom, Japan and France. Frequent co-authors include Farida Latif, Eamonn R. Maher, Dean Gentle, Christopher J. Ricketts, Dewi Astuti, Masahiro Yao, Takeshi Kishida, Emma R. Woodward, Noel W. Clarke and Maurice B. Hallett. Their work appears in journals such as Oncogene, Neuro-Oncology, The Journal of Pathology, American Journal of Medical Genetics Part C Seminars in Medical Genetics and Genes Chromosomes and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact